Autologous Dendritic Cell Transplantation as an Adjuvant Treatment in Pleomorphic Lung Carcinoma

Francisco S. Chung Jr.,1,2 Nelia S. Tan-Liu,1,3 Guia Imelda Elena R. Ladrera,1
Ramoncito S. Habaluyas,Ernesto DJ. Yuson,1 Joselito J. Danguilan,1
Samuel D. Bernal,4 Juanito A. Rubio1 and Maria Teresa A. Barzaga1,5

1Molecular Diagnostics and Cellular Therapeutics Lab,
Department of Pathology, Lung Center of the Philippines
2Department of Biochemistry and Molecular Biology, College of Medicine,
University of the Philippines Manila
3Department of Pathology, College of Medicine,
University of the Philippines Manila
4Globetek Science Foundation, Makati City
5Department of Microbiology, De La Salle Health Sciences Institute,
Dasmariñas City, Cavite

We embarked on autologous dendric cells (DC) transplantation as an adjuvant therapy with chemotherapy in a pleomorphic lung carcinoma patient. DC were isolated from PBMC and primed with the autologous tumor lysate. No adverse event was noted in DC transplantation. DC administration also correlated with immunomodulation, as evidenced by an approximately 5-fold increase in serum interferon gamma after 2 months. The utility of autologous DC transplantation may offer a clinical benefit with virtually no adverse event.

Key Words: autologous tumor priming, Dentritic Cell (DC), Interferon gamma